Tatjana Tallo

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND A substantial proportion of hepatitis C virus (HCV)-1b infected patients do not response to pegylated interferon-α plus ribavirin (PegIFNα/RBV) combination therapy that was partially associated with mutations in the non-structural 5A (NS5A) protein. OBJECTIVES Analysis of NS5A polymorphisms in HCV genotype 1b pre-treatment serum samples from(More)
  • 1